GlassScriptPhysician profile
Chakradhar Kotaru
NPI 1932209764
$61,036.90
in general payments reported to CMS, 2019-2025
21 companies · $8,244 in 2025
The $8,244 reported for 2025 was more than what 94% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $1,273 · 2021: $4,234 · 2022: $5,318 · 2023: $11K · 2024: $31K · 2025: $8,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Travel and Lodging: $11K · Education: $7,500 · Food and Beverage: $6,050 · Gift: $43.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,411.36 |
| Travel and Lodging | $11,048.35 |
| Education | $7,500.00 |
| Food and Beverage | $6,050.41 |
| Gift | $43.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $25,168.06 | 2020-2025 | Monarch Platform |
| Intuitive Surgical, INC. | $12,710.44 | 2020-2025 | Da Vinci Surgical System, Ion |
| Medical Device Business Services, INC. | $11,246.87 | 2022-2024 | Monarch Platform, Monarch |
| Astrazeneca Pharmaceuticals LP | $3,510.77 | 2021-2024 | Breztri, Fasenra |
| Olympus Corporation of The Americas | $1,862.49 | 2022 | |
| Abiomed | $1,844.30 | 2019-2025 | Impella |
| Noah Medical Corporation | $1,729.96 | 2023-2024 | Galaxy |
| Inari Medical, INC. | $954.37 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Getinge USA Sales, LLC | $868.69 | 2024 | Vasoview Hemopro 2 |
| Veran Medical Technologies, INC. | $187.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $175.32 | 2022-2025 | Winrevair |
| Penumbra, INC. | $173.33 | 2025 | Indigo System |
| Livanova USA, INC. | $130.79 | 2022 | |
| Edwards Lifesciences Corporation | $129.92 | 2023 | |
| Glaxosmithkline, LLC. | $108.59 | 2019-2025 | Nucala |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $72.54 | 2021-2025 | |
| Body Vision Medical INC. | $52.24 | 2023 | Lungvision |
| Grifols USA, LLC | $37.57 | 2024 | Prolastin-C Liquid |
| Pulmonx Corporation | $32.26 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.35 | 2025 | Jascayd |
| Amgen INC. | $15.91 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chakradhar Kotaru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.